144 related articles for article (PubMed ID: 31579984)
1. Oral bicalutamide for female pattern hair loss: A pilot study.
Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
[No Abstract] [Full Text] [Related]
2. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients.
Ismail FF; Meah N; Trindade de Carvalho L; Bhoyrul B; Wall D; Sinclair R
J Am Acad Dermatol; 2020 Nov; 83(5):1478-1479. PubMed ID: 32213304
[No Abstract] [Full Text] [Related]
3. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
4. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
5. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
6. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
7. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
8. Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia.
Lobon K; Pinczewski J; Bhoyrul B
Clin Exp Dermatol; 2022 Jan; 47(1):136-138. PubMed ID: 34192377
[No Abstract] [Full Text] [Related]
9. Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss.
Fernandez-Nieto D; Saceda-Corralo D; Jimenez-Cauhe J; Moreno-Arrones OM; Rodrigues-Barata R; Hermosa-Gelbard A; Vano-Galvan S
J Am Acad Dermatol; 2020 Nov; 83(5):e355-e356. PubMed ID: 32320770
[No Abstract] [Full Text] [Related]
10. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
[No Abstract] [Full Text] [Related]
11. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Garnick MB
BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
[No Abstract] [Full Text] [Related]
13. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
Jia AY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
[No Abstract] [Full Text] [Related]
15. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
16. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.
Kreher NC; Pescovitz OH; Delameter P; Tiulpakov A; Hochberg Z
J Pediatr; 2006 Sep; 149(3):416-20. PubMed ID: 16939760
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
18. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
19. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
[TBL] [Abstract][Full Text] [Related]
20. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
